Valneva: return to operating profit over 9m
(CercleFinance.com) - Valneva reports a net profit of E24.
7m for the first nine months of 2024, including proceeds from the sale of the priority review voucher, and an operating profit of E34.2m, vs. an operating loss of E57.2m a year earlier.
The vaccine company's total sales rose by just over 4% to E116.6m, including product sales of E112.5m, with Ixiaro/Jespect sales up 31% to E66m.
Valneva has revised its outlook for 2024, now anticipating total sales of E160m to E170m, total revenues of between E170m and E180m, and R&D expenditure of between E60m and E70m.
As we approach the conclusion of the Phase 3 trial in Lyme disease at the end of next year, we are entering a pivotal period in Valneva's evolution, management says.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
7m for the first nine months of 2024, including proceeds from the sale of the priority review voucher, and an operating profit of E34.2m, vs. an operating loss of E57.2m a year earlier.
The vaccine company's total sales rose by just over 4% to E116.6m, including product sales of E112.5m, with Ixiaro/Jespect sales up 31% to E66m.
Valneva has revised its outlook for 2024, now anticipating total sales of E160m to E170m, total revenues of between E170m and E180m, and R&D expenditure of between E60m and E70m.
As we approach the conclusion of the Phase 3 trial in Lyme disease at the end of next year, we are entering a pivotal period in Valneva's evolution, management says.
Copyright (c) 2024 CercleFinance.com. All rights reserved.